陈晖,王雷,贾三庆,严松彪,李虹伟,李桂华,孙志军,冯春光,张建维

• 1: 首都医科大学附属北京友谊医院心血管疾病诊治研究中心
• 2:首都医科大学附属北京友谊医院心血管疾病诊治研究中心
• 3:首都医科大学附属北京友谊医院心血管疾病诊治研究中心
• 4:首都医科大学附属北京友谊医院心血管疾病诊治研究中心

摘要(Abstract)：

目的观察在病变冠状动脉中置入西罗莫司洗脱支架(sirolimus eluting stents,SES,Cypher)和紫杉醇洗脱支架(paclitaxel eluting stents,PES,Taxus)的安全性、主要心脏不良事件(main ad-verse cardiac events,MACEs)情况。方法连续入选北京友谊医院心血管中心2002年12月至2004年12月接受SES和PES两种药物支架置入的患者中资料完整及完成随防者224例,其中男性168例,女性56例,平均年龄60·9±11·1岁(35~86岁)。采用门诊和电话方式进行随访,平均随访13·4±6·7个月(3~27个月)。结果两组患者的基础情况差异无统计学意义。两组患者均没有急性和亚急性血栓发生,但PES组有2例迟发性血栓发生。PES组发生MACE6例,其中2例急性心肌梗死,4例患者进行了靶病变血运重建;SES组有1例患者进行了靶病变血运重建。结论两种药物支架的置入降低了患者的MACE发生率,SES组的迟发性血栓事件、MACE发生率均低于PES组。

关键词(KeyWords)： 西罗莫司;紫杉醇;支架;冠状动脉疾病

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 陈晖,王雷,贾三庆,严松彪,李虹伟,李桂华,孙志军,冯春光,张建维

参考文献(References)：

• [1]Morice MC,Serruys PW,Sousa JE,et al.Arandomized comparison of a sirolimus-elutingstent with a standard stent for coronaryrevascu-larization.NEngl J Med,2002,346:1773-1780.
• [2]Moses JW,Leon MB,Popma JJ,et al.Sirolimus-Eluting Stents ver-sus Standard Stentsin Patients with Stenosisin a Native Coronary Ar-tery.NEngl J Med,2003,349:1315-1323.
• [3]Schampaert E,Cohen EA,Schluter M.The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesionsinsmall native coronary arteries(C-SIRIUS).J AmColl Car-diol,2004,43:1110-1115.
• [4]Schofer J,Schluter M,Gershlick AH,et al.Sirolimus-elutingstents for treatment of patients withlong atherosclerotic lesionsin small cor-onary arteries:double-blind,randomised controlled trial(E-SIRI-US).Lancet,2003,362:1093-1099.
• [5]Grube E,Silber S,Hauptmann KE.TAXUS I:six-and twelve-monthresultsfroma randomized,double-blindtrial on a slow-release paclitaxel-eluting stent for de novo coronary lesions.Circulation,2003,107:38-42.
• [6]Colombo A,Drzewiecki J,Banning A,et al.Randomized Study to Assessthe Effectiveness of Slow-and Moderate-Release Polymer-Based Paclitaxil-Eluting Stents for Coronary Artery Ledions.Circulation,2003,108:788-794.
• [7]Stone GW,Ellis SG,Cox DA,et al.Apolymer-based,paclitaxel-eluting stent in patients with coronary artery disease.NEngl J Med,2004,350:221-231.
• [8]Perin EC.Drug-eluting stent:a comparison between CYPHER and TAXUS.Rev Cardiovasc Med,2005,6(Suppl1):S13-21.
• [9]Moussa I,Leon MB,Baim DS,et al.Impact of Sirolimus-Eluting Stents on Outcomes in Diabetic Patients:ASIRIUS Substudy.Circu-lation,2004,109:2273-2278.
• [10]Park SJ,Kim YH,Lee BK.Sirolimus-eluting stent implantation for unprotectedleft main coronary artery stenosis:comparison with bare metal stent implantation.J AmColl Cardiol,2005,45:351-356.
• [11]Kastrati A,Mehilli J,von Beckerath N,et al.Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrencesin patients withcoronaryin-stent restenosis:a random-ized controlledtrial.JAMA,2005,293:165-171.
• [12]Tanabe K,Serruys PW,Grube E.TAXUS III Trial:in-stent rest-enosis treated with stent-based delivery of paclitaxel incorporatedin a slow-release polymer formulation.Circulation,2003,107:559-564.